|[April 03, 2014]
Reveal Biosciences - The First Certified Preclinical Services Laboratory to Offer Advanced Cell Diagnostics RNAscope® In Situ Hybridization Technology
SAN DIEGO --(Business Wire)--
Reveal Biosciences, LLC, a leading preclinical services laboratory for
advanced tissue technologies, is pleased to announce the availability of
Advanced Cell Diagnostics' (ACD) RNAscope® in situ hybridization
(ISH) technology. With this collaboration, Reveal Biosciences becomes
the first ACD Certified RNAscope® Service Provider to bring RNAscope® to
researchers in the preclinical space.
RNAscope® is a novel RNA ISH technology that brings the benefits of in
situ analysis to RNA biomarkers. This technology is compatible with
FFPE specimens, conventional chromogenic and fluorescent dyes, and is
suitable for bright-field microscopy and multiplex analysis. Although
novel, this technology is already used in over 75 peer-reviewed
publications in cancer, stem cell, neuroscience, and other applications.
Reveal will combine the sensitivity of the RNAscope® assay with
the power of ImageDx, their proprietary image analysis software, to
provide quantitative ISH data from preclinical cell and tissue samples.
"Reveal Biosciences already delivers RNA data and quantification to
pharmaceutical clients within preclinical oncology by combining
RNAscope® with ImageDx, our proprietary image analysis software,"
said Dr. Claire Weston, CEO and Founder of Reveal Biosciences. "We
are thrilled to extend our portfolio of advanced tissue diagnostic
services to offer RNAscope® technology to a wider range of
pharmaceutical and biotechnology customers in oncology and other
therapeutic areas. We believe RNAscope® technology, with its unique
ability to deliver molecular detection while preserving morphological
context in a single assay will continue its trajectory in changing the
landscape of RNA biomarker screening and validation in tissues for
research, molecular diagnostics, and companion diagnostics."
Advanced Cell Diagnostics introduced the Certified RNAscope® Service
Provider program with the goal to enable laboratories to support
pharmaceutical clients via delivery of high quality pathology testing
services. Each service provider receives extensive training on RNAscope®
technology and is required to pass a rigorous certification procedure. "The
Reveal Biosciences team have proven themselves in automated
immunohistochemistry, imaging, and image analysis. Their stellar
reputation among researchers and comprehensive service portfolio makes
them an ideal partner for deployment of our RNAscope® platform,"
said Evangeline Gonzalez, Chief Commercial Officer at ACD.
About Reveal Biosciences
Reveal Biosciences is a leading contract research organization that
specializes in advanced tissue technology services and tissue-based
research. Their portfolio of services includes histology,
immunohistochemistry (IHC), immunofluorescence (IF), proprietary
multiplex technology, whole slide imaging, and image
analysis/quantification, as well as novel RNA ISH technologies, such as
RNAscope. Reveal Biosciences is also applying their expertise in
advanced tissue technologies to develop innovative diagnostics and
companion diagnostics. Learn more about Reveal Biosciences' full
range of advanced tissue technology services at http://www.revealbiosciences.com.
About Advanced Cell Diagnostics
Advanced Cell Diagnostics, Inc. (ACD) is a leader in molecular
pathology, developing cell and tissue-based research tools for all areas
of biomedical research, and diagnostic tests for personalized medicine.
The company's products and services are based on its proprietary
RNAscope® technology, the most sensitive method available for RNA in
situ hybridization capable of single molecule detection and multiplex
analysis. RNAscope technology can turn RNA into powerful biomarkers by
providing important molecular and morphological context that is lost
with conventional analysis technologies. ACD partners with
pharmaceutical and biotechnology companies to validate biomarkers for
targeted therapeutic development in cancer and other diseases. These
partnerships provide the foundation for ACD to develop companion
diagnostic tests in conjunction with partners' targeted therapeutics.
ACD also pursues internal programs to develop proprietary diagnostic
tests in cancer management. Learn more about ACD and RNAscope®
technology at www.acdbio.com.
[ Back To TMCnet.com's Homepage ]